# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-114022
Filing Date
2024-10-10
Accepted
2024-10-10 14:14:11
Documents
59
Period of Report
2024-08-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | neog-20240831.htm iXBRL | 10-Q | 1294768
2 | EX-31.1 | neog-ex31_1.htm | EX-31.1 | 14494
3 | EX-31.2 | neog-ex31_2.htm | EX-31.2 | 14294
4 | EX-32 | neog-ex32.htm | EX-32 | 11337
5 | GRAPHIC | img193737124_0.jpg | GRAPHIC | 646845
| Complete submission text file | 0000950170-24-114022.txt |  | 7937195

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | neog-20240831.xsd | EX-101.SCH | 1354458
61 | EXTRACTED XBRL INSTANCE DOCUMENT | neog-20240831_htm.xml | XML | 891018

Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 10-Q | Act: 34 | File No.: 000-17988 | Film No.: 241364791
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)